Fujian Cosunter Pharmaceutical Co., Ltd. Class A

Fujian Cosunter Pharmaceutical Co., Ltd. Class A

SSZSE:300436
67.59
CNY
-3.21
(-4.53%)
-1.48EPS
14.06BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A carries a market capitalization of 14.06B, placing it among publicly traded companies globally. Its enterprise value stands at 13.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.06B
Enterprise Value13.84B

Share Statistics

As of September 30, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A has 168.03M shares outstanding.

Shares Outstanding168.03M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 31.47, and the price-to-book ratio stands at 17.17.

PS Ratio31.47
PB Ratio17.17
P/TBV Ratio25.71

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 32.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.84B versus a market cap of 14.06B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales32.25

Financial Position

As of September 30, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A maintains a current ratio of 2.07, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 51.49, indicating elevated leverage, while an interest coverage ratio of -6.53 demonstrates limited ability to service its debt obligations.

Current Ratio2.07
Quick Ratio1.50
Debt / Equity51.49
Debt / EBITDA-2.15
Interest Coverage-6.53

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -37.76, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.40, reflecting losses generated across the asset base. The company generates approximately 600,374.61 in revenue per employee across its workforce of 715.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.20 indicates how many times Fujian Cosunter Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-37.76
Return on Assets (ROA)-12.40
Revenue Per Employee600,374.61
Employee Count715.00
Inventory Turnover1.20

Taxes

CNY

Over the twelve months ended September 30, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A recorded 11.03M in income tax expense. The company reported a pretax loss of -228.21M and -209.82M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax11.03M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A's stock has declined approximately 32.40% over the past 52 weeks. The 50-day moving average sits at 80.83, while the 200-day moving average is 98.67.

52-Week Price Change-32.40%
50-Day Moving Average80.83
200-Day Moving Average98.67

Income Statement

CNY

Over the twelve months ended September 30, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A generated 429.27M in revenue and converted that into -209.82M in net income, yielding earnings per share of -1.48. EBITDA reached -225.79M, while operating income came in at -84.56M.

Revenue429.27M
Gross Profit263.04M
Operating Income-84.56M
Pretax Income-228.21M
Net Income-209.82M
EBITDA-225.79M
EBIT-225.79M
Earnings Per Share (EPS)-1.48

Balance Sheet

CNY

As of September 30, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A holds 826.08M in cash and equivalents against 485.04M in total debt, resulting in a net debt position of -416.74M. Total book value stands at 818.71M, with working capital of 588.75M providing operational flexibility.

Cash & Cash Equivalents826.08M
Total Debt485.04M
Net Debt-416.74M
Equity (Book Value)818.71M
Book Value Per Share4.87
Working Capital588.75M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-81.35M

Margins

Over the twelve months ended September 30, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A posted a gross margin of 61.28, reflecting its pricing power and cost economics. The operating margin of -19.70 and net profit margin of -48.88 provide insight into operational efficiency.

Gross Margin61.28
Operating Margin-19.70
Pretax Margin-53.16
Profit Margin-48.88
EBITDA Margin-52.60

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A paid dividends of 0.09 per share. The dividend payout ratio of -5.71 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -5.06, meaning Fujian Cosunter Pharmaceutical Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.09
Payout Ratio-5.71
Shareholder Yield-5.06

Stock Splits

Fujian Cosunter Pharmaceutical Co., Ltd. Class A's most recent stock split took place on September 16, 2015 with a 1:2 split ratio.

Last Split Date9/16/2015
Split Ratio1:2

Scores

As of September 30, 2026, Fujian Cosunter Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 7.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.71